A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics with AZD0780 following repeated dose administration in healthy adults with elevated LDL-C levels

Inclusion Criteria

• Inclusion Criteria:
• • Healthy participants with suitable veins for cannulation or repeated venipuncture.
• • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
• • Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.
• • Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
• • Have a body mass index between 18 and 35 kg/m2 inclusive and weigh at least 50 kg.
• • Fasting LDL-C ≥ 70 mg/dL and < 190 mg/dL at Screening.
• Exclusion Criteria:
• • History of any clinically important disease or disorder.
• • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration.
• • Any abnormal vital signs or laboratory values including clinical chemistry, hematology, coagulation, or urinalysis results.
• • Current smokers or those who have smoked or used nicotine products (including e‑cigarettes) or any known or suspected history of alcohol or drug abuse.
• • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, especially to drugs with a similar chemical structure or class to AZD0780.